Skip to main content
. Author manuscript; available in PMC: 2015 Sep 24.
Published in final edited form as: Clin Immunol. 2013 Dec 17;150(2):184–191. doi: 10.1016/j.clim.2013.12.001

Figure 1.

Figure 1

CD27−CD21− B-cells are relatively overrepresented in B-cell pool in hepatitis C and hepatitis C-related cirrhosis. A. Gating strategy used to quantify CD27−CD21− B-cells. B. Frequency of CD27−CD21− B-cells in healthy donors (HD), non-cirrhotic HCV-infected patients (non-CIR HCV), HCV cirrhotic (HCV CIR), hepatocellular carcinoma (HCC) and non-HCV cirrhotic (non-HCV CIR). C. Geometric mean fluorescence intensity of CD95 in CD27/CD21-defined B-cell subsets in all patient cohorts. D. Geometric mean fluorescence intensity of CD95 in CD27−CD21− B-cell across patient cohorts. E. Frequency of CD21−CD95hi B-cells across patient cohorts. p-Values by the Wilcoxon tests.